ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

ASCO GU 2022: First-Line Pembrolizumab in Advanced Urothelial Carcinoma: Clinical Parameters Associated with Efficacy in the Phase 2 KEYNOTE-052 and Phase 3 KEYNOTE-361 Trials

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

Immunotherapy for head and neck cancer: Present and future - ScienceDirect

Deeper insights into combinations of immune checkpoint inhibitors with other drug classes - memoinOncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Targeting HER2-positive breast cancer: advances and future directions

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

IJMS, Free Full-Text

Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities, Journal of Hematology & Oncology

Frontiers Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

PDF) Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Esophageal cancer: taking immunotherapy one step further - memoinOncology